Dangerous Drug Alert: FDA puts "black box" warning on anti-seizure drug Potiga for risk of vision loss and skin problems.

The FDA required "black box" label changes to the anti-seizure medication Potiga (ezogabine),  These are the most serious label changes the FDA can require.  The drug, manufactured by GlaxoSmithKline, carries "risks of abnormalities to the retina in the eye, potential vision loss, and skin discoloration, all of which may become permanent."  The FDA recommends that patients have eye exams both before starting the dangerous drug and every six months during treatment. See this FDA press release for more information.